Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II

Launched by GRIN THERAPEUTICS, INC. · Apr 26, 2024

Keywords

ClinConnect Summary

The Astroscape trial is studying a medication called radiprodil to see how safe it is and how well it works for patients with Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) type II. This study is for individuals aged 18 to 65 who have not found relief from their seizures with at least two different anti-seizure medications. To participate, candidates must have a confirmed diagnosis of TSC or FCD and experience a certain number of seizures over a month.

Participants in this study will take radiprodil for up to six months initially, and if it shows promise, they may continue treatment for another year. During the trial, everyone will receive the same medication, and researchers will monitor their health closely to ensure safety. It’s important to note that participants should have stable treatment for their epilepsy for at least 28 days before starting the trial. This research aims to provide new insights into managing seizures and behavioral symptoms for those affected by these conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Failed to respond to at least 2 anti-seizure medications (ASMs) at appropriate dosages and duration.
• * Disease specific criteria:
• • 1. diagnosis of FCD Type II based on clinical symptoms and confirmed by a positive magnetic resonance imaging (MRI)
• • 2. diagnosis of TSC by either clinical or genetic diagnostic criteria (Northrup, 2021) as documented in the participant's medical record.
• • Participant on average has had at least 8 countable/witnessed primary seizures during a 4-week baseline period with at least 1 seizure occurring in at least 3 of the 4 weeks of baseline
• • All medical interventions for epilepsy / behavior (including ketogenic diet and any neurostimulation devices) should be stable for 28 days prior to screening with no more than 6 days per month use of rescue medication. Participants must remain on a stable regimen throughout the treatment period.
• • Participant has had an MRI scan within 12 months of the planned date of first dose of study drug.
• Exclusion Criteria:
• • Any other clinically relevant medical, neurologic, or psychiatric condition and/or behavioral disorder unrelated to TSC or FCD Type II that would preclude or jeopardize participant's safe participation or administration of study drug or the conduct of the study according to the judgement of the investigator.
• • Clinically significant laboratory or ECG abnormalities.
• • Severe hepatic dysfunction (Child-Pugh grade C).
• • History of brain surgery within 6 months of screening for epilepsy or any other reason.
• • Contraindications to radiprodil or with known hypersensitivity to the active substance or the excipients or other chemically closely related substances.
• • Receiving treatment with contraindicated concomitant drugs such as agonists or antagonists of the glutamate receptor, including but not limited to felbamate, memantine, and perampanel.
• • body weight \<10kg for whom a gastric tube is the only possibility for radiprodil dosing.